Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 321 participants.
Also called NCT04811092
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 321 participants
- Registry
-
NCT04811092 -
2023-509139-16-00 -
U1111-1309-6312 -
2021-000199-12
-
- Other papers using this trial's data
- Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Croatia, Czechia, Denmark, France, Germany, Greece, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Serbia, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT04811092. Randomized; double masking; primary purpose treatment. Start 2022-03-18 (actual); primary completion 2025-04-03 (actual). Results posted on 2026-04-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)
- Acronym
- HYPERION
- Condition
- Pulmonary Arterial Hypertension
- Intervention (Drug)
- Sotatercept
- Intervention (Other)
- Placebo
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Record details
- Record id
cardio:ct-nct04811092- Content hash
a56c86c828f046f32f48134e647c3bd0fc743210c40f7c868a42ddc24bcc767b